Compositions and methods for elimination of gram negative bacteria
AssigneesAssistance Publique-Hopitaux de Paris, Da Volterra, Universite Paris Diderot—Paris 7
InventorsAntoine Andremont, Jean De Gunzburg, Francois Lescure
Life of this patent
Estimating the term…
Abstract
Oral drug delivery formulations which specifically administer antibacterial agents to the ileum, caecum, and/or the colon, without significant administration elsewhere in the gastrointestinal tract, are disclosed. The formulations include, as actives, a combination of a macrolide or aminoglysoside, or quinolone antibacterial and an anti-Gram-negative lipopeptide (polymyxin) antibacterial agent or other peptide antibacterials effective against Gram-negative bacteria. The formulations can be used to treat infections or unwanted colonization in the colon, and to provide effective decontamination of the colonic flora from unwanted or potentially pathogenic bacteria.
Claims25
A composition comprising a drug delivery system that is orally administered, and delivers specifically to the late ileum, caecum, or colon, and substantially avoids delivery to other areas of the gastrointestinal tract, wherein the drug delivery system comprises:
- a) an aminoglycoside, quinolone or macrolide antibacterial, and
- b) an anti-Gram-negative lipopeptide antibacterial or other peptide antibacterial effective against Gram-negative bacteria.
A set of a first and a second compositions, wherein
- the first composition comprises an aminoglycoside, macrolide or quinolone antibacterial, and
- the second composition comprises a drug delivery system that is orally administered, and delivers specifically to the late ileum, caecum, or colon, and substantially avoids delivery to other areas of the gastrointestinal tract, wherein the drug delivery system comprises an anti-Gram-negative lipopeptide antibacterial or other peptide antibacterial effective against Gram-negative bacteria.
A kit comprising:
- a first composition comprising a drug delivery system that is orally administered, and delivers specifically to the late ileum, caecum, or colon, and substantially avoids delivery to other areas of the gastrointestinal tract, wherein the drug delivery system comprises an anti-Gram-negative lipopeptide antibacterial or other peptide antibacterial effective against Gram-negative bacteria, and
- a second composition comprising an aminoglycoside, macrolide or quinolone antibacterial.
Dependencies are inferred from the claim text.